AI-assisted IVF websites promise precision while leaving out the safeguards patients need
Websites selling AI-assisted IVF products have become more than marketing tools. They now function as clinical decision influencers, shaping how couples and fertility specialists perceive embryo selection, oocyte assessment, sperm analysis, and ovarian stimulation optimization before any interaction with a clinic ever occurs. A content analysis of 21 companies found a consistent pattern: the public-facing message leans hard toward benefit, while risks, limitations, and privacy protections are largely absent.
Every website in the review promoted some advantage of AI use in assisted reproduction. The most common claim was improved accuracy, appearing on 13 sites. The language was uniform in its optimism and sparse in its caution. When a technology is presented as more accurate without equivalent discussion of false reassurance, model error, or context-specific failure, the marketing message can slide past informed consent and into persuasion.
One sentence captures the imbalance plainly: none of the websites explicitly outlined risks of AI use.
Limited disclosure around model development weakens informed choice
The review looked not just at whether companies mentioned AI, but at how much technical substance they provided. Most sites, 20 of 21, described their systems in some way, yet the detail often stopped at broad promotional language. Only 7 disclosed sample sizes used to develop the AI tools, and just 5 described dataset diversity or representativeness. In a field where performance depends on the quality and breadth of training data, that omission matters because algorithmic accuracy can collapse when a model is applied outside the population on which it was built.
The companies collectively offered 30 AI tools across several fertility applications, including embryo quality assessment, oocyte quality assessment, sperm analysis, endometrial receptivity analysis, and ovarian stimulation optimization. Those are not minor add-ons. Each one can influence a treatment pathway, embryo transfer decisions, or the perception that a cycle has been processed through a more objective lens. When a patient sees a tool described as intelligent but cannot find the underlying evidence base, the product becomes difficult to evaluate as a medical aid rather than a brand claim.
Independent coding of a subset of websites achieved almost perfect agreement, with Cohen’s kappa ranging from 0.831 to 1.000, lending methodological weight to the content analysis itself. The findings were not a product of vague interpretation. They were stable enough to show that the same communication pattern repeated across companies and jurisdictions.
Privacy language exists, but AI-specific protections do not
Digital fertility products sit in a particularly sensitive category because they handle health data, reproductive data, and often highly personal decision-making. Thirteen websites linked to privacy policies, yet none included provisions specifically addressing patient health data processing when AI products or services were involved. Eight websites mentioned data protection measures on product introduction pages, including encryption and de-identification. Five referred to GDPR compliance and three referenced HIPAA compliance.
Those references sound reassuring until they are placed under scrutiny. General privacy language is not the same as an AI-specific policy that explains what data are collected, how long they are stored, whether they are used to retrain models, who can access them, and how a patient can withdraw consent. Fertility patients are being asked to trust systems whose outputs may affect embryo selection or stimulation strategies, yet the websites rarely explain how data flow through those systems. In reproductive medicine, opacity in data handling is not an abstract legal issue. It touches autonomy, confidentiality, and the right to understand how intimate information is being processed.
The absence of AI-specific privacy provisions also raises a practical concern about cross-border compliance. The companies were based in Europe, Israel, Canada, the United States, and China. A patchwork of jurisdictional claims on a website does not tell a patient how local data protections are operationalized or whether the company has adapted policies to the actual deployment of its product.
Direct-to-consumer marketing raises the stakes for fertility patients
Most of the companies, 19 of 21, said clinician oversight or final decision-making remained in place. That language suggests a familiar safeguard: the human clinician remains the gatekeeper. Two companies, however, used direct-to-consumer marketing models, bypassing the traditional clinic-centered pathway.
Direct marketing in fertility care is especially fraught because patients often arrive in a state of urgency, disappointment, or fear of losing time. In that setting, claims of uniqueness carry disproportionate force. Nine companies described their products as unique or as the “first” in the IVF industry, and 6 referenced patent information. Those claims may support brand differentiation, but they do little to establish clinical benefit. A patent is not proof of superior patient outcomes, and “first” does not tell a patient whether a model has been validated across diverse populations or whether it performs reliably in routine practice.
The ethical issue is not limited to exaggeration. It extends to the structure of persuasion itself. When a company sells AI directly to consumers, the patient is asked to interpret complex technical claims without the counterweight of a clinician’s explanation. That can distort expectations, especially when the site emphasizes precision while omitting uncertainty.
A marketing message built on confidence, not balance
The analysis also found no AI-specific privacy language in any of the websites and no explicit discussion of risk. Balanced communication would include both sides of the ledger: where the tool may help, where it may fail, and what type of evidence supports its use. Instead, the public narrative centers on performance claims such as increased accuracy, often without the supporting details that let a lay reader judge the scope of those claims.
In reproductive medicine, where the emotional and financial cost of IVF is already high, an algorithmic tool can appear to offer control over a process that often feels uncertain. That appeal is understandable. It also makes communication standards more important, not less. A website that suggests improved success while withholding evidence about training data, validation, and risks may create a false sense of precision around a technology that still depends on careful clinical integration.
The paper argues for truthful advertising, balanced disclosure of risks, separate AI-specific privacy policies, and ethics review mechanisms to verify claims before they reach patients. Those proposals are grounded in a straightforward clinical reality: reproductive decisions should not be shaped by marketing prose that outpaces the evidence.
What the website review can and cannot prove
The study examined 21 companies identified through searches and abstracts presented at the 2022 ESHRE annual meeting, with website content captured in August 2023 and reviewed again in June 2026 after external feedback. It remains a website analysis, not an audit of actual regulatory compliance, technical architecture, or clinical outcomes. The findings therefore speak to public claims, not verified performance in practice.
Even with that limit, the pattern is difficult to ignore. Across a global set of AI-assisted IVF providers, the web presence was far more comfortable promising benefit than explaining risk, and far more willing to invoke data protection than to spell out AI-specific handling of reproductive health information. For patients making decisions under emotional pressure, that gap can shape consent before the first consultation ever begins.